Cytran's IM862 fails KS Phase III

Cytran (Kirkland, Wash.) said that IM862 monotherapy did not meet its primary efficacy objectives in a double-blind, placebo-controlled Phase III trial of 202 patients with AIDS-related Kaposi's sarcoma (KS). The company said the product was safe and had a good side effect profile. Cytran said it will continue trials of IM862, a peptide that inhibits angiogenesis and regulates cytokines, in combination with chemotherapy in early stage KS and will other tumor types, including ovarian, colorectal and breast cancer. The company plans to conduct further analyses of the Phase III trial, including examining the effect of HAART on the outcome and evaluating secondary endpoints of time to disease progression and duration of response. ...